iShares Neuroscience and Healthcare ETF(IBRN · ETF)
ETF quote, holdings, sector allocation, technicals, and options analytics.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
Snapshot
$34.91
- 52-Week Range
- $21.78 – $37.00
- YTD
- +9.83%
- IV Rank (30D)
- 41.25
- Straddle Price
- $2.60
Info
iShares Neuroscience and Healthcare ETF (IBRN) ETF
- Exchange
- ARCX
- Inception
- 2022-08-24
- Has Options
- Yes
ETF Profile
holdings as of 2026-07-31
Holdings
68
AUM
$4.9M
Provider
iShares (BlackRock)
Inception
2022-08-24
Exchange
ARCX
Data As Of
2026-07-31
Expense Ratio
—
Dividend Yield
0.92%
Distribution
Semi-Annual
Recent distributions
| Ex-Date | Pay Date | Amount | Type |
|---|---|---|---|
| 2025-12-16 | 2025-12-19 | $0.3198 | CD |
| 2024-12-17 | 2024-12-20 | $0.1011 | CD |
| 2023-12-20 | 2023-12-27 | $0.0063 | CD |
| 2023-06-07 | 2023-06-13 | $0.0082 | CD |
Asset Allocation
Top Holdings
top 50 of 68 holdings
| Symbol | Name | Weight % | Asset Class | Country |
|---|---|---|---|---|
| — | BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares | 13.30% | Short-term investment | US |
| PRAX | Praxis Precision Medicines Inc | 5.02% | Equity (common) | US |
| AXSM | AXSOME THERAPEUTICS, INC. | 4.90% | Equity (common) | US |
| ALKS | ALKERMES PUBLIC LIMITED COMPANY | 4.55% | Equity (common) | IE |
| BIIB | BIOGEN INC. | 3.93% | Equity (common) | US |
| SRRK | Scholar Rock Holding Corp | 3.91% | Equity (common) | US |
| PTCT | PTC THERAPEUTICS, INC. | 3.88% | Equity (common) | US |
| DNLI | Denali Therapeutics Inc | 3.71% | Equity (common) | US |
| — | argenx SE | 3.70% | Other | NL |
| ACAD | ACADIA PHARMACEUTICALS INC. | 3.63% | Equity (common) | US |
| XENE | Xenon Pharmaceuticals Inc | 3.61% | Equity (common) | CA |
| CPRX | CATALYST PHARMACEUTICALS, INC. | 3.53% | Equity (common) | US |
| NBIX | NEUROCRINE BIOSCIENCES, INC. | 3.47% | Equity (common) | US |
| SUPN | SUPERNUS PHARMACEUTICALS, INC. | 3.44% | Equity (common) | US |
| — | CENTESSA PHARMACEUTICALS PLC | 3.10% | Other | GB |
| — | SK Biopharmaceuticals Co Ltd | 3.01% | Equity (common) | KR |
| EWTX | Edgewise Therapeutics Inc | 2.82% | Equity (common) | US |
| AVDL | AVADEL PHARMACEUTICALS PUBLIC LIMITED COMPANY | 2.64% | Equity (common) | IE |
| SRPT | SAREPTA THERAPEUTICS, INC. | 2.64% | Equity (common) | US |
| DYN | Dyne Therapeutics Inc | 2.46% | Equity (common) | US |
| DNTH | Dianthus Therapeutics Inc | 2.46% | Equity (common) | US |
| — | H. LUNDBECK A/S | 2.35% | Equity (common) | DK |
| AXGN | AxoGen, Inc. | 2.06% | Equity (common) | US |
| — | BioArctic AB | 1.82% | Equity (common) | SE |
| BHVN | Biohaven Ltd | 1.68% | Equity (common) | VG |
| — | Neuren Pharmaceuticals Ltd | 1.65% | Equity (common) | NZ |
| TSHA | Taysha Gene Therapies Inc | 1.32% | Equity (common) | US |
| — | Dynavox Group AB | 1.24% | Equity (common) | SE |
| CAPR | Capricor Therapeutics Inc | 1.15% | Equity (common) | US |
| — | Idorsia Ltd | 1.03% | Equity (common) | CH |
| ANNX | Annexon Inc | 1.01% | Equity (common) | US |
| RAPP | Rapport Therapeutics Inc | 0.98% | Equity (common) | US |
| IART | INTEGRA LIFESCIENCES HOLDINGS CORPORATION | 0.96% | Equity (common) | US |
| — | SanBio Company Limited | 0.91% | Equity (common) | JP |
| — | Zylox-Tonbridge Medical Technology Co Ltd | 0.81% | Equity (common) | CN |
| DRUG | Bright Minds Biosciences Inc | 0.80% | Equity (common) | CA |
| — | Medincell SA | 0.72% | Equity (common) | FR |
| FULC | Fulcrum Therapeutics Inc | 0.68% | Equity (common) | US |
| RGNX | Regenxbio Inc | 0.68% | Equity (common) | US |
| — | MicroPort NeuroScientific Corp | 0.62% | Equity (common) | KY |
| CBLL | Ceribell Inc | 0.60% | Equity (common) | US |
| AVXL | Anavex Life Sciences Corp | 0.56% | Equity (common) | US |
| VNDA | VANDA PHARMACEUTICALS INC. | 0.54% | Equity (common) | US |
| BNTC | Benitec Biopharma Inc | 0.52% | Equity (common) | US |
| NPCE | Neuropace Inc | 0.51% | Equity (common) | US |
| — | PEIJIA MEDICAL LIMITED | 0.50% | Equity (common) | KY |
| PRTA | Prothena Corporation PLC | 0.50% | Equity (common) | IE |
| SLDB | Solid Biosciences Inc | 0.49% | Equity (common) | US |
| — | Oncolys Biopharma Inc | 0.41% | Equity (common) | JP |
| CLPT | Clearpoint Neuro Inc | 0.41% | Equity (common) | US |
Geographic Breakdown
Fund Holdings
iShares Neuroscience and Healthcare ETF ·
NPORT-P period 2026-07-31
(filed 2026-03-25)
Net assets:
$5M
· 68 total positions
· equity 93.10%
· non-equity 20.24%
| # | Symbol | Issuer | Weight | Value |
|---|---|---|---|---|
| 1 | PRAXIS PRECISION MEDICINES INC | Praxis Precision Medicines Inc | 5.02% | $245548 |
| 2 | AXSOME THERAPEUTICS INC | AXSOME THERAPEUTICS, INC. | 4.90% | $239341 |
| 3 | ALKERMES PLC | ALKERMES PUBLIC LIMITED COMPANY | 4.55% | $222590 |
| 4 | BIOGEN INC | BIOGEN INC. | 3.93% | $192302 |
| 5 | SCHOLAR ROCK HOLDING CORP | Scholar Rock Holding Corp | 3.91% | $190928 |
| 6 | PTC THERAPEUTICS INC | PTC THERAPEUTICS, INC. | 3.88% | $189580 |
| 7 | DENALI THERAPEUTICS INC | Denali Therapeutics Inc | 3.71% | $181268 |
| 8 | ACADIA PHARMACEUTICALS INC | ACADIA PHARMACEUTICALS INC. | 3.63% | $177543 |
| 9 | XENON PHARMACEUTICALS INC | Xenon Pharmaceuticals Inc | 3.61% | $176630 |
| 10 | CATALYST PHARMACEUTICALS INC | CATALYST PHARMACEUTICALS, INC. | 3.53% | $172773 |
| 11 | NEUROCRINE BIOSCIENCES INC | NEUROCRINE BIOSCIENCES, INC. | 3.47% | $169667 |
| 12 | SUPERNUS PHARMACEUTICALS INC | SUPERNUS PHARMACEUTICALS, INC. | 3.44% | $168223 |
| 13 | SK BIOPHARMACEUTICALS CO LTD | SK Biopharmaceuticals Co Ltd | 3.01% | $146948 |
| 14 | EDGEWISE THERAPEUTICS INC | Edgewise Therapeutics Inc | 2.82% | $137851 |
| 15 | AVADEL PHARMACEUTICALS PLC | AVADEL PHARMACEUTICALS PUBLIC LIMITED COMPANY | 2.64% | $129084 |
| 16 | SAREPTA THERAPEUTICS INC | SAREPTA THERAPEUTICS, INC. | 2.64% | $128874 |
| 17 | DYNE THERAPEUTICS INC | Dyne Therapeutics Inc | 2.46% | $120453 |
| 18 | DIANTHUS THERAPEUTICS INC | Dianthus Therapeutics Inc | 2.46% | $120288 |
| 19 | H LUNDBECK A S | H. LUNDBECK A/S | 2.35% | $115013 |
| 20 | AXOGEN INC | AxoGen, Inc. | 2.06% | $100542 |
| 21 | BIOARCTIC AB | BioArctic AB | 1.82% | $89204 |
| 22 | BIOHAVEN LTD | Biohaven Ltd | 1.68% | $82065 |
| 23 | NEUREN PHARMACEUTICALS LTD | Neuren Pharmaceuticals Ltd | 1.65% | $80474 |
| 24 | TAYSHA GENE THERAPIES INC | Taysha Gene Therapies Inc | 1.32% | $64610 |
| 25 | DYNAVOX GROUP AB | Dynavox Group AB | 1.24% | $60763 |
Showing top 25 of 56 equity holdings.
Non-equity holdings
— 12 positions,
20.24% of NAV
| Category | Weight | Value | Positions |
|---|---|---|---|
| Short-term investment | 13.34% | $652077 | 2 |
| Other | 6.90% | $337547 | 10 |
Price History
Seasonality
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | +1.49% | 4 |
| Feb | -4.18% | 4 |
| Mar | -3.76% | 4 |
| Apr | +1.20% | 4 |
| May | -1.17% | 4 |
| Jun | -1.32% | 4 |
| Jul | +4.03% | 3 |
| Aug | -2.12% | 4 |
| Sep | +0.59% | 4 |
| Oct | +3.45% | 4 |
| Nov | +3.72% | 4 |
| Dec | +1.72% | 4 |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $34.66
SMA 50: $34.70
SMA 200: $31.33
Current: $34.84
EMA 12: $34.62
EMA 26: $34.67
MACD: -0.0488 | Signal: -0.0579
BULLISH
ADX (14): 15.74
RANGE
+DI: 40.58
−DI: 26.66
Momentum Oscillators
RSI (14): 51.32
NEUTRAL
Stoch %K: 26.11
Stoch %D: 26.41
Williams %R: -61.24
Volume & Volatility
BB Upper: $35.86
BB Lower: $33.45
NEUTRAL
OBV: 90,302
Vol SMA 20: 1,841
Vol ROC: 331.89%
ATR: $0.80
True Range: $0.54
HV 20: 30.5%
HV 30: 26.5%
HV 60: 29.1%
Data Summary
Data Points: 500
Last Updated: 2026-06-12T21:15:14.785000
Date Range: 2024-06-14T00:00:00 – 2026-06-12T00:00:00
AI Analysis
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
News
Options Activity
- IV Rank (30D)
- 41.25
- IV Rank (7D)
- 87.06
- Avg IV
- 52.0%
- Straddle (30D)
- $2.60
- Straddle (7D)
- $1.75
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Volatility Surface
Enter a ticker to render the implied volatility surface.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
- Beta (1Y vs SPY)
- 1.20
- Correlation (SPY)
- 57.7%
- R²
- 0.33
- Ann. Volatility
- 25.7%
- SPY Volatility
- 12.3%
Above average volatility - stock moves with market amplification
Beta & Alpha Over Time
Constituent Performance
Click any bar to view the full quote for that stock.
Constituents
| Symbol | Price | 1 Day | 1 Week | 1 Month |
|---|